CD40LG and COVID-19: In the control group of non-COVID-19 stroke no patients were positive for the aPL tests used, whereas in the COVID-19 patients without vascular thrombosis 2/20 (10%) resulted positive for IgM aCL and anti-β2-GPI antibodies (Table 3).